Amneal Pharmaceuticals, Inc.
American publicly traded generics and specialty pharmaceutical company
AMRX NYSE
ISIN US03168L1052 SEC CIK 1723128 LEI 549300VV176ZO5WQHZ61
Follow Amneal Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$862.7M
+10% vs same quarter last year
Net income
−$21.7M
−1015.8% vs same quarter last year
EPS, diluted
−$0.06
−700% vs same quarter last year
Operating cash flow
$98.3M
−17% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $3B | $72.1M |
| FY24 | $2.8B | −$116.9M |
| FY23 | $2.4B | −$84M |
| FY22 | $2.2B | −$270.6M |
| FY21 | $2.1B | $13.2M |
| FY20 | $2B | $67.8M |
| FY19 | $1.6B | −$603.6M |
| FY18 | $1.7B | −$19.7M |
| FY17 | $1B | $0 |
| FY16 | $1B | $0 |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 36.9% | 13.1% | 2.4% |
| FY24 | 36.5% | 8.9% | −4.2% |
| FY23 | 34.3% | 8.5% | −3.5% |
| FY22 | 35.5% | −4.3% | −12.2% |
| FY21 | 36.7% | 7.3% | 0.6% |
| FY20 | 31.5% | 4.6% | 3.4% |
| FY19 | 21.7% | −15.3% | −37.1% |
| FY18 | 43.1% | −1.2% | −1.2% |
| FY17 | 50.9% | 23.7% | 0% |
| FY16 | 58.7% | 28% | 0% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $269.9M |
| FY24 | $243.2M |
| FY23 | $302.4M |
| FY22 | $18.7M |
| FY21 | $194.1M |
| FY20 | $322.6M |
| FY19 | −$45.5M |
| FY18 | $167.1M |
| FY17 | $139.4M |
| FY16 | −$7.7M |
Show the numbers
| Year | Dividends |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | $0 |
| FY19 | $0 |
| FY18 | $183M |
| FY17 | $375.3M |
| FY16 | $200.6M |
- Amneal Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Amneal Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | 2.4% | −30.6% |
| FY24 | −4.2% | −47% |
| FY23 | −3.5% | −58% |
| FY22 | −12.2% | −80.4% |
| FY21 | 0.6% | −71.9% |
| FY20 | 3.4% | −62.2% |
| FY19 | −37.1% | −46.3% |
| FY18 | −1.2% | −49.6% |
| FY17 | 0% | −45.9% |
| FY16 | 0% | −36% |